Aprea Therapeutics Inc（APRE）财务数据APREAprea Therapeutics Inc

Evaluating the bottom line, Aprea Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -47.44%, provide a clear picture of how effectively APRE converts its operational activities into shareholder value.

In the context of the broader market, APRE competes directly with industry leaders such as AZTR and TOVX. With a market capitalization of $10.83M, it holds a significant position in the sector. When comparing efficiency, APRE's gross margin of N/A stands against AZTR's N/A and TOVX's 100.00%. Such benchmarking helps identify whether Aprea Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Aprea's total revenue has seen a decline, with Q2 2026 reporting $0, but its gross margin remains high at 100% for previous quarters, indicating potential for profitability if revenues increase.